{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T08:17:08Z","timestamp":1788337028226,"version":"build-2803163510"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T00:00:00Z","timestamp":1684540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Tofacitinib is an oral Janus kinase inhibitor for the treatment of ulcerative colitis (UC). Real-world data comparing the effectiveness of tofacitinib to ustekinumab are limited. We compared 52-week outcomes of tofacitinib vs ustekinumab for UC after antitumor necrosis factor (anti-TNF) failure.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this retrospective cohort study, adults initiated tofacitinib or ustekinumab for UC after anti-TNF failure May 1, 2018 to April 1, 2021, at a US academic medical center. The primary outcome was steroid-free clinical remission (SFCR) at 12 and 52 weeks. The secondary outcome was drug survival (ie, time to drug discontinuation due to nonresponse). Adverse events (AEs) were also assessed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Sixty-nine patients initiated tofacitinib, and 97 patients initiated ustekinumab with median follow-up of 88.0 and 62.0 weeks, respectively. After inverse probability of treatment-weighted logistic and Cox regression, there was no association of tofacitinib vs ustekinumab with SFCR at 12 weeks (odds ratio, 1.65; 95% CI, 0.79-3.41), SFCR at 52 weeks (odds ratio, 1.14; 95% CI, 0.55-2.34), or drug survival (hazard ratio, 1.37; 95% CI, 0.78-2.37). Kaplan-Meier analysis demonstrated no separation in drug survival curves. Regression results were similar after excluding patients with prior tofacitinib or ustekinumab exposure. During available follow-up, 17 AEs were reported for tofacitinib (most commonly shingles, n\u2005=\u20054), and 10 AEs were reported for ustekinumab (most commonly arthralgia and rash, each n\u2005=\u20052). Two patients discontinued treatment due to AEs (1 tofacitinib for elevated liver enzymes, 1 ustekinumab for arthralgia).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In a real-world UC cohort, tofacitinib and ustekinumab demonstrated similar effectiveness at 52 weeks. Adverse events were consistent with the known safety profiles of these agents.<\/jats:p><\/jats:sec>","DOI":"10.1093\/ibd\/izad087","type":"journal-article","created":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T20:42:03Z","timestamp":1684615323000},"page":"395-401","source":"Crossref","is-referenced-by-count":12,"title":["1-Year Comparative Effectiveness of Tofacitinib vs Ustekinumab for Patients With Ulcerative Colitis and Prior Antitumor Necrosis Factor Failure"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4622-8441","authenticated-orcid":false,"given":"Rahul S","family":"Dalal","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, Hepatology and Endoscopy, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puza P","family":"Sharma","sequence":"additional","affiliation":[{"name":"Pfizer Inc , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanwal","family":"Bains","sequence":"additional","affiliation":[{"name":"Department of Nutrition, Brigham and Women\u2019s Hospital, Harvard Medical School , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan C","family":"Pruce","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Hepatology and Endoscopy, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3585-2425","authenticated-orcid":false,"given":"Jessica R","family":"Allegretti","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Hepatology and Endoscopy, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,5,20]]},"reference":[{"issue":"18","key":"2024030114271797400_CIT0001","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med."},{"issue":"13","key":"2024030114271797400_CIT0002","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as induction and maintenance therapy for ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med."},{"issue":"10","key":"2024030114271797400_CIT0003","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/j.cgh.2020.01.008","article-title":"First- and second-line pharmacotherapies for patients with moderate to severely active ulcerative colitis: an updated network meta-analysis","volume":"18","author":"Singh","year":"2020","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"4","key":"2024030114271797400_CIT0004","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1093\/ibd\/izac121","article-title":"Tofacitinib Response in Ulcerative Colitis (TOUR): early response after initiation of tofacitinib therapy in a real-world setting","volume":"29","author":"Long","year":"2022","journal-title":"Inflamm Bowel Dis."},{"issue":"9","key":"2024030114271797400_CIT0005","first-page":"516","article-title":"Efficacy and safety of tofacitinib in the treatment of ulcerative colitis: real-life experience in Andalusia","volume":"114","author":"Hern\u00e1ndez Mart\u00ednez","year":"2022","journal-title":"Rev Esp Enferm Dig."},{"issue":"1","key":"2024030114271797400_CIT0006","doi-asserted-by":"crossref","first-page":"17562848211064004","DOI":"10.1177\/17562848211064004","article-title":"Real-world experience with tofacitinib in ulcerative colitis: a systematic review and meta-analysis","volume":"14","author":"Lucaciu","year":"2021","journal-title":"Therap Adv Gastroenterol"},{"issue":"2","key":"2024030114271797400_CIT0007","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.dld.2021.11.009","article-title":"Short-term effectiveness and safety of tofacitinib in ulcerative colitis - real world data from tertiary medical centers in Israel","volume":"54","author":"Avni-Biron","year":"2022","journal-title":"Dig Liver Dis."},{"issue":"5","key":"2024030114271797400_CIT0008","doi-asserted-by":"crossref","first-page":"354","DOI":"10.34172\/aim.2021.52","article-title":"Efficacy and safety of tofacitinib for treatment of moderate to severe active ulcerative colitis: first report from Iran","volume":"24","author":"Jameshorani","year":"2021","journal-title":"Arch Iran Med."},{"issue":"1","key":"2024030114271797400_CIT0009","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/ibd\/izab011","article-title":"Real-world effectiveness and safety of tofacitinib in patients with ulcerative colitis: systematic review with meta-analysis","volume":"28","author":"Taxonera","year":"2022","journal-title":"Inflamm Bowel Dis."},{"issue":"11","key":"2024030114271797400_CIT0010","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1093\/ecco-jcc\/jjab070","article-title":"Effectiveness and safety of ustekinumab in ulcerative colitis: real-world evidence from the ENEIDA Registry","volume":"15","author":"Chaparro","year":"2021","journal-title":"J Crohns Colitis."},{"issue":"2","key":"2024030114271797400_CIT0011","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1093\/ecco-jcc\/jjaa177","article-title":"effectiveness and safety of ustekinumab intensification at 90 mg every four weeks in Crohn\u2019s disease: a multicenter study","volume":"15","author":"Fumery","year":"2020","journal-title":"J Crohns Colitis"},{"issue":"10","key":"2024030114271797400_CIT0012","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1016\/j.cgh.2021.03.028","article-title":"Predictors and outcomes of ustekinumab dose intensification in ulcerative colitis: a multicenter cohort study","volume":"20","author":"Dalal","year":"2021","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"11","key":"2024030114271797400_CIT0013","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1080\/14712598.2021.1981855","article-title":"One-year effectiveness and safety of ustekinumab in ulcerative colitis: a multicenter real-world study from Italy","volume":"21","author":"Chiappetta","year":"2021","journal-title":"Expert Opin Biol Ther."},{"issue":"7","key":"2024030114271797400_CIT0014","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/ueg2.12275","article-title":"Ustekinumab treatment in ulcerative colitis: real-world data from the Swedish inflammatory bowel disease quality register","volume":"10","author":"Thunberg","year":"2022","journal-title":"United European Gastroenterol J"},{"issue":"1","key":"2024030114271797400_CIT0015","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1177\/2050640619895361","article-title":"Clinical outcomes with ustekinumab as rescue treatment in therapy-refractory or therapy-intolerant ulcerative colitis","volume":"8","author":"Ochsenk\u00fchn","year":"2020","journal-title":"United European Gastroenterol J"},{"issue":"11","key":"2024030114271797400_CIT0016","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/apt.15717","article-title":"Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real-world cohort study","volume":"51","author":"Amiot","year":"2020","journal-title":"Aliment Pharmacol Ther."},{"issue":"10","key":"2024030114271797400_CIT0017","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1093\/ibd\/izab097","article-title":"Real-world comparison of tofacitinib vs ustekinumab among bio-exposed patients with ulcerative colitis: a propensity score analysis","volume":"27","author":"Dalal","year":"2021","journal-title":"Inflamm Bowel Dis."},{"issue":"1","key":"2024030114271797400_CIT0018","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/gut.43.1.29","article-title":"A simple clinical colitis activity index","volume":"43","author":"Walmsley","year":"1998","journal-title":"Gut."},{"issue":"12","key":"2024030114271797400_CIT0019","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1093\/ibd\/izz089","article-title":"Hospitalization outcomes for inflammatory bowel disease in teaching vs nonteaching hospitals","volume":"25","author":"Dalal","year":"2019","journal-title":"Inflamm Bowel Dis."},{"issue":"3","key":"2024030114271797400_CIT0020","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1023\/A:1020363010465","article-title":"Using propensity scores to help design observational studies: application to the tobacco litigation","volume":"2","author":"Rubin","year":"2001","journal-title":"Health Services and Outcomes Research Methodology. 2001\/12\/01"},{"issue":"3","key":"2024030114271797400_CIT0021","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"issue":"1","key":"2024030114271797400_CIT0022","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s10620-022-07472-1","article-title":"Comparative long-term drug survival of vedolizumab, adalimumab, and infliximab in biologic-na\u00efve patients with ulcerative colitis","volume":"68","author":"Dalal","year":"2022","journal-title":"Dig Dis Sci."}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izad087\/50411838\/izad087.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/30\/3\/395\/56731999\/izad087.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/30\/3\/395\/56731999\/izad087.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,20]],"date-time":"2024-10-20T20:28:00Z","timestamp":1729456080000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/30\/3\/395\/7174954"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,20]]},"references-count":22,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,5,20]]},"published-print":{"date-parts":[[2024,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izad087","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,3,1]]},"published":{"date-parts":[[2023,5,20]]}}}